Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA ; volume:24 ; number:1 ; day:16 ; month:8 ; year:2024 ; pages:1-11 ; date:12.2024
BMC cancer ; 24, Heft 1 (16.8.2024), 1-11, 12.2024
- Urheber
-
Chen, Jennifer H.
Addanki, Sridevi
Roy, Dhruvajyoti
Bassett, Roland
Kalashnikova, Ekaterina
Spickard, Erik
Kuerer, Henry M.
Meas, Salyna
Sarli, Vanessa N.
Korkut, Anil
White, Jason B.
Rauch, Gaiane M.
Tripathy, Debu
Arun, Banu K.
Barcenas, Carlos H.
Yam, Clinton
Sethi, Himanshu
Rodriguez, Angel A.
Liu, Minetta C.
Moulder, Stacy L.
Lucci, Anthony
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-024-12689-6
- URN
-
urn:nbn:de:101:1-2411032100236.358880767711
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chen, Jennifer H.
- Addanki, Sridevi
- Roy, Dhruvajyoti
- Bassett, Roland
- Kalashnikova, Ekaterina
- Spickard, Erik
- Kuerer, Henry M.
- Meas, Salyna
- Sarli, Vanessa N.
- Korkut, Anil
- White, Jason B.
- Rauch, Gaiane M.
- Tripathy, Debu
- Arun, Banu K.
- Barcenas, Carlos H.
- Yam, Clinton
- Sethi, Himanshu
- Rodriguez, Angel A.
- Liu, Minetta C.
- Moulder, Stacy L.
- Lucci, Anthony
- SpringerLink (Online service)
Ähnliche Objekte (12)
Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Microwave imaging for neoadjuvant chemotherapy monitoring: initial clinical experience
Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer
Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
Does T1c–2N0–1M0 triple negative breast cancer derive a benefit from neoadjuvant chemotherapy?
Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Microwave imaging for neoadjuvant chemotherapy monitoring: initial clinical experience
Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer
Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
Does T1c–2N0–1M0 triple negative breast cancer derive a benefit from neoadjuvant chemotherapy?
Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Microwave imaging for neoadjuvant chemotherapy monitoring: initial clinical experience
Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer
Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience